8-K: GoodRx Reports Mixed Q1 2024 Results: Revenue Growth Offset by Legal Settlement Costs

GoodRx's first quarter of 2024 saw revenue growth of 8% year-over-year, but was impacted by a legal settlement and restructuring costs.

Summary

• GoodRx reported a revenue of $197.9 million for the first quarter of 2024, an 8% increase compared to the same period last year.
• The company experienced a net loss of $1.0 million, with a net loss margin of 0.5%.
• Adjusted net income was $32.6 million, with an adjusted net income margin of 16.5%.
• Adjusted EBITDA reached $62.8 million, resulting in an adjusted EBITDA margin of 31.7%.
• The company's prescription transactions revenue increased by 8%, driven by a 10% increase in monthly active consumers.
• Subscription revenue decreased by 6% due to the sunset of the Kroger Savings Club partnership.
• Pharma manufacturer solutions revenue grew by 20%, indicating strong market penetration.
• GoodRx repurchased 21.3 million shares of Class A common stock for $154.8 million during the quarter.
• The company has $295.2 million remaining under its share repurchase program.
• GoodRx is guiding for second quarter revenue of approximately $200 million and full year revenue between $800 million and $810 million.
• The full year revenue guidance includes a $25 million impact from the de-prioritization of vitaCare and the sunset of the Kroger Savings Club, as well as the ongoing effect of the Change Healthcare outage.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to revenue growth and strong adjusted EBITDA, but tempered by a net loss and the impact of a legal settlement and restructuring costs. The company's guidance is positive, but there are some headwinds.

Positives

• GoodRx saw an 8% increase in revenue and adjusted revenue year-over-year.
• The company's adjusted EBITDA margin was a strong 31.7%.
• Prescription transactions revenue grew by 8%, driven by a 10% increase in monthly active consumers.
• Pharma manufacturer solutions revenue increased by 20%, showing strong growth in that segment.
• The company repurchased a significant number of shares, indicating confidence in its value.
• GoodRx raised its full-year revenue guidance to $800-$810 million.
• The company expects to achieve over $250 million of Adjusted EBITDA for the full year, up about 15% from 2023.

Negatives

• GoodRx reported a net loss of $1.0 million for the quarter.
• Subscription revenue decreased by 6% due to the sunset of the Kroger Savings Club partnership.
• General and administrative expenses increased by 39%, primarily due to a $13 million legal settlement loss.
• The full year revenue guidance includes a $25 million impact from the de-prioritization of vitaCare and the sunset of the Kroger Savings Club, as well as the ongoing effect of the Change Healthcare outage.

Risks

• The company's performance is subject to changes in medication pricing and the pricing structures negotiated by industry participants.
• GoodRx relies on a limited number of industry participants, including pharmacy benefit managers, pharmacies, and pharma manufacturers.
• The company faces competition in the industry.
• There are risks related to government regulation of the internet, e-commerce, consumer data and privacy, information technology and cybersecurity.
• The company's ability to utilize net operating loss carryforwards and certain other tax attributes is a risk.
• There is a risk that GoodRx may be unable to realize expected benefits from its restructuring and cost reduction efforts.
• The company faces litigation related risks.
• The recent healthcare reform legislation and other changes in the healthcare industry and in healthcare spending may adversely affect the business.

Future Outlook

GoodRx is guiding for second quarter revenue of approximately $200 million, representing approximately 5% year-over-year growth, and Adjusted EBITDA Margin in the low thirty-percent range. For the full year 2024, the company is raising its guidance for revenue and Adjusted Revenue to be between $800 million and $810 million, representing approximately 6% growth on an adjusted basis at the midpoint. The company expects to achieve over $250 million of Adjusted EBITDA for the full year.

Management Comments

• Scott Wagner, Interim Chief Executive Officer, stated that he is encouraged by the strides made since he joined a year ago and that the company has made progress against a clear set of priorities which have reignited growth, enhanced the core value proposition and strengthened the business model.
• Karsten Voermann, Chief Financial Officer, stated that the company is guiding to revenue and Adjusted Revenue of approximately $200 million for the second quarter and between $800 million and $810 million for the full year, and that the company will continue to prioritize cash conversion and disciplined capital deployment.

Industry Context

GoodRx operates in the competitive healthcare technology sector, focusing on prescription savings. The company's performance is influenced by factors such as medication pricing, relationships with pharmacy benefit managers, and consumer adoption of digital health solutions. The growth in pharma manufacturer solutions revenue indicates a positive trend in the company's ability to expand its offerings and market penetration.

Comparison to Industry Standards

• GoodRx's adjusted EBITDA margin of 31.7% is relatively strong compared to other healthcare technology companies, but it is important to compare this to companies with similar business models.
• Companies like SingleCare and Optum Rx also operate in the prescription savings space, and their financial metrics would be relevant for comparison.
• The 8% revenue growth is a positive sign, but it is important to consider the impact of the $25 million top-line impact associated with the de-prioritization of vitaCare, as well as the anticipated sunset of the Kroger Savings Club.
• The share repurchase program is a common practice among public companies, but the size and timing of the repurchases should be compared to industry benchmarks.

Legal Proceedings

• The company recognized a net $13.0 million estimated legal settlement loss in the first quarter of 2024 with respect to an ongoing litigation.

Stakeholder Impact

• Shareholders will be impacted by the share repurchase program and the company's financial performance.
• Employees may be affected by the company's restructuring and cost reduction efforts.
• Customers will continue to benefit from the company's prescription savings offerings.
• Suppliers and creditors will be impacted by the company's financial health and capital allocation decisions.

Next Steps

• GoodRx management will host a conference call and webcast on May 9, 2024, to discuss the results and the company's business outlook.
• The company will continue to focus on its capital allocation priorities, including investing for profitable growth, paying down debt, buying back shares, and M&A that aligns with its strategic priorities.

Key Dates

Keywords

GoodRx, prescription savings, pharmacy, healthcare, revenue, EBITDA, net income, share repurchase, financial results, monthly active consumers